Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.

ABSTRACT:

Background

The incidence of stage I and stage II lung adenocarcinoma (LUAD) is likely to increase with the introduction of annual screening programs for high-risk individuals. We aimed to identify a reliable prognostic signature with immune-related genes that can predict prognosis and help making individualized management for patients with early-stage LUAD.

Methods

The public LUAD cohorts were obtained from the large-scale databases including 4 microarray data sets from the Gene Expression Omnibus (GEO) and 1 RNA-seq data set from The Cancer Genome Atlas (TCGA) LUAD cohort. Only early-stage patients with clinical information were included. Cox proportional hazards regression model was performed to identify the candidate prognostic genes in GSE30219, GSE31210 and GSE50081 (tr

SUBMITTER: Wu P 

PROVIDER: S-EPMC7542703 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature